AGIOS director receives new option and RSU grants

AGIOS PHARMACEUTICALS director Maykin Ho reported compensation-related equity transactions.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS director Maykin Ho reported compensation-related equity transactions. She exercised restricted stock units into 2,816 shares of common stock, bringing her direct holdings to 19,848 shares. She also received 14,950 stock options and 2,927 new restricted stock units, which vest in future years.

Insider Trade Summary

2,816 shares exercised/converted

Exercise 4 txns

Insider Ho Maykin

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	2,816	$0.00	$0.00
Grant/Award	Restricted stock units	2,927	$0.00	$0.00
Grant/Award	Stock options (right to buy)	14,950	$0.00	$0.00
Exercise	Common stock	2,816	$0.00	$0.00

Holdings After Transaction: Restricted stock units — 2,927 contracts (Direct); Stock options (right to buy) — 14,950 contracts (Direct); Common stock — 19,848 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

RSUs exercised into common stock: 2,816 shares Common shares held after transactions: 19,848 shares New stock options granted: 14,950 options +4 more

7 metrics

RSUs exercised into common stock 2,816 shares Converted from restricted stock units on June 18, 2026

Common shares held after transactions 19,848 shares Direct holdings following June 18, 2026 Form 4 transactions

New stock options granted 14,950 options Grant on June 18, 2026, right to buy common stock

Option exercise price $34.16 per share Exercise price for 14,950 stock options expiring June 18, 2036

New RSUs granted 2,927 units Restricted stock units granted June 18, 2026, vesting June 18, 2027

RSUs vesting date (2025 grant) June 18, 2026 Vesting date for RSUs granted June 18, 2025 that were exercised

Option expiration date June 18, 2036 Expiration for 14,950 stock options granted June 18, 2026

Key Terms

Restricted stock units, Stock options (right to buy), Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more

5 terms

Restricted stock units financial

"The restricted stock units were granted on June 18, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock options (right to buy) financial

"Stock options (right to buy) … were granted on June 18, 2026."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common stock financial

"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AGIOS (AGIO) director Maykin Ho report in this Form 4?

Maykin Ho reported equity compensation activity, including exercising 2,816 restricted stock units into common shares and receiving new grants of 14,950 stock options and 2,927 restricted stock units, all held directly as part of her director compensation.

How many AGIOS (AGIO) common shares does Maykin Ho hold after these transactions?

After exercising 2,816 restricted stock units into common stock, Maykin Ho directly holds 19,848 shares of AGIOS Pharmaceuticals common stock, according to the Form 4 totals reported following the transactions on June 18, 2026.

What stock options were granted to Maykin Ho by AGIOS (AGIO)?

She was granted 14,950 stock options with a $34.16 exercise price, expiring June 18, 2036. These options vest as to 100% of the underlying shares on June 18, 2027, reflecting a typical long-term equity incentive for a director.

What restricted stock units did Maykin Ho receive from AGIOS (AGIO)?

She received 2,927 restricted stock units on June 18, 2026. Each unit represents a right to one common share and will vest in full on June 18, 2027, with vested shares delivered within three business days after vesting.

Were there any open-market buys or sells by Maykin Ho in this AGIOS (AGIO) filing?

No open-market purchases or sales were reported. All transactions involved exercises of restricted stock units and grants of stock options and new restricted stock units, which are standard equity compensation awards rather than market trades.

When did the earlier AGIOS (AGIO) restricted stock units granted to Maykin Ho vest?

Restricted stock units granted on June 18, 2025 vested in full on June 18, 2026. The vested shares from these units are delivered to the reporting person within three business days after vesting, per the Form 4 footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 05:21 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ho Maykin

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/18/2026		M		2,816	A	$0	19,848	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		M			2,816	⁽²⁾	⁽²⁾	Common stock	2,816	$0	0	D
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽³⁾	⁽³⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽⁴⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as Attorney-in-fact for Maykin Ho	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR